Table 3.
Univariate analyses for 90-day outcomes of total hip arthroplasty.
| Complications | Matched non-HS patients | Matched HS patients | P-value |
|---|---|---|---|
| Sample size | 1906 | 477 | |
| Any adverse events | 416 (21.8%) | 108 (22.6%) | .71 |
| Severe adverse events | 147 (7.7%) | 33 (6.9%) | .63 |
| Surgical site infection | 43 (2.3%) | 12 (2.5%) | .73 |
| Sepsis | 50 (2.6%) | 21 (4.4%) | - |
| Deep vein thrombosis | 77 (4.0%) | 17 (3.6%) | - |
| Pulmonary embolism | 44 (2.3%) | ∗ | - |
| Myocardial infarction | 25 (1.3%) | ∗ | - |
| Cardiac arrest | ∗ | ∗ | - |
| Pancreatitis | 14 (0.7%) | ∗ | - |
| Minor adverse events | 403 (21.1%) | 112 (23.5%) | .26 |
| Wound dehiscence | 29 (1.5%) | 18 (3.8%) | .003 |
| Pneumonia | 83 (4.4%) | 27 (5.7%) | - |
| Urinary tract infection | 258 (13.5%) | 68 (14.3%) | - |
| Acute kidney injury | 127 (6.7%) | 30 (6.3%) | - |
| Transfusion | 128 | 16 | - |
| Hematoma | 29 (1.5%) | ∗ | - |
HS, hidradenitis suppurativa.
Bold indicates significance of P < .05.
An ∗ indicates less than 10 patients.